Benedict J Panizza (Benedict Panizza, B Panizza)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Squamous Cell Carcinoma

Prognostic Factors

Top Venues

ANZ journal of surgery

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Cancer immunology, immunotherapy : CII

Journal of neuro-oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jean-Michel Bourque, Benedict J Panizza
Documented Initial Growth Does Not Necessarily Indicate Treatment for Sporadic Vestibular Schwannomas. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 45 (8) (2024)
Catherine Barnett, James Bowman, Rahul Ladwa, Margaret McGrath, Howard Liu, Mitesh Gandhi, Syeda Farah Zahir, Sandro Porceddu, Benedict J Panizza
Long-term outcomes in advanced anterior skull base malignancy: a single quaternary institution experience. ANZ journal of surgery (2024)
Stijn Bekkers, Linda Stewart, Benedict J Panizza
Time is function and survival. ANZ journal of surgery 93 (10) (2023)
Annika Antonsson, Marjorie M A de Souza, Benedict J Panizza, David C Whiteman
Sexual debut and association with oral human papillomavirus infection, persistence and oropharyngeal cancer-An analysis of two Australian cohorts. International journal of cancer 151 (5) (2022)
James Nightingale, Mitesh Gandhi, Jonathan Helena, James Bowman, Margaret McGrath, Jermaine I G Coward, Sandro Porceddu, Rahul Ladwa, Benedict J Panizza
Immunotherapy for the treatment of perineural spread in cutaneous head and neck squamous cell carcinoma: Time to rethink treatment paradigms. Head & neck 44 (5) (2022)
Janin Chandra, W P Woo, N Finlayson, Howard Yu-Hao Liu, M McGrath, Rahul M Ladwa, M Brauer, Y Xu, S Hanson, Benedict J Panizza, Ian Hector Frazer, Sandro V Porceddu
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC). Cancer immunology, immunotherapy : CII 70 (3) (2020)
E Guazzo, Benedict J Panizza
Management of advanced adenoid cystic carcinoma infiltrating the skull base: a contemporary review. Journal of neuro-oncology 150 (3) (2020)